An innovative biopharmaceutical company

with integrated commercialization platform

spanning the entire biologics value chain

About Tasly Biopharma

Founded in 2001, Tasly Biopharma has over 20 years of experience in autonomous R&D and commercialization of biological drugs and has developed integrated commercial platforms in the industry which integrate R&D, manufacturing, and sales of biological drugs.

Being a leading innovative biomedical company in China, Tasly Biopharma has established a complete biological medicine research and development system. The company expands its product line of research and development through a wide variety of ways such as autonomous R&D, joint development, authorized introduction and acquisition of commercial rights. Currently, Tasly Biopharma has an extensive product portfolio of 17 biological medicine projects in three major therapeutic areas of cardiovascular diseases, oncology and autoimmune diseases, and alimentary tract and metabolism, aiming to provide first-in-class/best-in-class biological drugs with affordable prices for global patients and meet the growing unfulfilled clinical needs in the target therapeutic area.

Tasly Biopharma has relatively strong scientific research capabilities and has conducted or participated in scientific research projects, such as three national “Major Innovative Drug Development” projects, three Torch Programs, and New Product project and biomedical industry transformation, etc. We have successfully developed and commercialized our leading thrombolytic biological drug PUK, which is the only approved recombinant human prourokinase product in China. PUK is the first Category I biological drug approved in China to have received funding under the National Science and Technology Major Project — Major Innovative Drug Development during the 11th Five-Year Plan. This product is very likely to become a domestic blockbuster in the treatment for cardiovascular diseases.

By far

We have a product portfolio of more than 17 biological assets, including one Category I innovative biologic thrombolytic drug PUK on the market, two pioneer product in NDA, two products in Phase II clinical trial, three products in Phase I clinical trial and nine preclinical products. This makes up a preferred product portfolio capable of continuous development to allow more patients worldwide to benefit from high-quality and cost-effective innovative biologic drugs.

17

A product portfolio of 17 biological assets

1

1 new indications for PUK coming soon

3

Received 3 fundings under the National Science and Technology Major Project — Major Innovative Drug Development

3

Three Torch Programs, New Product Project, and biomedical industry transformation

Honours

2019

Rated as the patent pilot company in Shanghai

2018

SY101 received funding under the National Science and Technology Major Project — Major Innovative Drug Development during the 13th Five-Year Plan at the same time

2017

PUK won the award of the "Innovative Biological Drug with the Most Clinical Values"

2017

APE (B1140)received funding under the National Science and Technology Major Project — Major Innovative Drug Development during the 13th Five-Year Plan

2014

Became one of the 100 new enterprises in national high-tech zones

2013

PUK won the honorary title of "Shanghai Famous Brand"

2012

In 2012, PUK was selected and included in the Torch Program and New Product Project of the Ministry of Science and Technology

2011

PUK received funding under the National Science and Technology Major Project — Major Innovative Drug Development during the 11th Five-Year Plan

2009

The industrialization project of PUK was included in the Shanghai Science and Technology Committee's biomedical industry transformation project

2008

Recognized as one of the high-tech enterprises in Shanghai